Q3 Financial Results 2024-25

AI SummaryClose X

Beximco Pharmaceuticals PLC reported strong financial results for the nine months ended March 31, 2025, with net revenue increasing by 10.8% to BDT 36,622.0 million (£235.0 million), driven by an 8.5% rise in domestic sales and a significant 45.6% surge in export sales to BDT 3,004.3 million (£19.3 million). Profit after tax saw a substantial 20.3% increase, reaching BDT 5,261.0 million (£33.8 million). The third quarter also demonstrated robust growth, with net revenue up 14.8% to BDT 12,608.6 million (£80.9 million) and profit after tax climbing 26.3% to BDT 1,726.0 million (£11.1 million).

Disclaimer*

UK 100

Latest directors dealings